Select Language
IgE Fc
IgE Fc Overview
| English Name | Immunoglobulin E | Approved Drugs | 5 |
| Drugs in Clinical Trials | 19 | Target Synonym | Immunoglobulin E |
| Highest Development Stage | Approved | ||
| English Name | Immunoglobulin E |
| Target Synonym | Immunoglobulin E |
| Approved Drugs | 5 |
| Drugs in Clinical Trials | 19 |
| Highest Development Stage | Approved |
IgE Fc Product List
- Product Category
Protein (4)
- Product Status
Launched (4)
- Species
Human (2)Cynomolgus (1)Mouse (1)
- Tag
His Tag (3)His Tag & Avi Tag (1)
- Conjugate
Unconjugated (3)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT IGE-H52H9 |  Human | HEK293 | Human IgE Fc Protein, His Tag (MALS verified) |  |  |  |
IGE-H82E3 | Human | HEK293 | Biotinylated Human IgE Fc Protein, His,Avitag™ |  | | |
IGE-M52H3 |  Mouse | HEK293 | Mouse IgE Fc Protein, His Tag (MALS verified) |  | | |
IGE-C52H3 |  Cynomolgus | HEK293 | Cynomolgus IgE Fc Protein, His Tag (MALS verified) |  | | |
Total: 4
- 1
IgE Fc Background
As one of the five designated immunoglobulin isotypes, immunoglobulin E (IgE) plays a major role in atopic conditions by inducing immediate hypersensitivity reactions. IgE also contributes significantly to the body’s immune response to parasitic infections. IgE antibodies are predominantly found in the tissues, firmly attached to effector cells, such as mast cells and basophils, by high-affinity IgE Fc receptor (Fc epsilon RI) and low-affinity IgE receptor (Fc epsilon RII).
IgE Fc Synonyms
IgE
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Omalizumab biosimilar (Reliance Life Sciences) | R-TPR-022 | Phase 3 Clinical | Reliance Life Sciences | Asthma | Details |
| Omalizumab biosimilar (Teva) | TEV-45779 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Chronic Urticaria | Details |
| Ligelizumab | QGE-031 | Phase 3 Clinical | Tanox Inc | Asthma; Chronic Urticaria; Dermatitis, Atopic; Food Hypersensitivity; Hypersensitivity; Peanut Hypersensitivity; Pemphigoid, Bullous; Urticaria | Details |
| Omalizumab biosimilar (Curateq Biologics) | BP11; BP-11 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Chronic Urticaria | Details |
| Ozureprubart | JYB-1904; RPT-904 | Phase 3 Clinical | Jiangsu Jiye Biopharmaceutical Co Ltd | Allergic asthma; Asthma; Chronic Urticaria; Food Hypersensitivity; Rhinitis, Allergic; Rhinitis, Allergic, Perennial; Urticaria | Details |
| LP-003 (Tianchen Biomedical) | LP-003 | Phase 3 Clinical | Longbio Pharma (Suzhou) Co Ltd | Allergic asthma; Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Food Hypersensitivity; Hypersensitivity; Nasal Polyps; Respiratory Tract Diseases; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Sinusitis; Urinary Tract Infections | Details |
| Recombinant anti-IgE monoclonal antibody(Cspc Baike) | Phase 3 Clinical | Cspc Baike (Shandong) Biopharmaceutical Co Ltd | Asthma; Chronic Urticaria | Details | |
| Anti-CEmX monoclonal antibody (Fountain Biopharma) | h4B12; FB-825 | Phase 2 Clinical | Academia Sinica | Asthma; Dermatitis, Atopic | Details |
| UB-221 | UB-221 | Phase 2 Clinical | Chinese Academy Of Sciences | Chronic Urticaria | Details |
| Omalizumab biosimilar (Glenmark) | GBR-310 | Phase 2 Clinical | Glenmark Pharmaceuticals Ltd | Asthma; Chronic Urticaria | Details |
| Bifidobacterium Bifidum（Sun Yat-sen University） | Phase 2 Clinical | Sun Yat-Sen University | Carcinoma, Hepatocellular | Details | |
| ADP-101 | ADP-101 | Phase 2 Clinical | Alladapt Immunotherapeutics Inc | Food Hypersensitivity | Details |
| Omalizumab biosimilar (Hisun BioRay) | HS632; HS-632 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Asthma | Details |
| Omalizumab biosimilar (Fountain BioPharma) | FB-317 | Phase 1 Clinical | Academia Sinica | Asthma; Urticaria | Details |
| JZB-34 | AAFP; JZB-34 | Phase 1 Clinical | Shanghai Kexin Biotech Co Ltd | Hypersensitivity | Details |
| PHB-050 | PHB-050; PHB050 | Phase 1 Clinical | Poplar Therapeutics Inc | Asthma; Dermatitis, Atopic; Food Hypersensitivity | Details |
| IGNX-001 | IGNX-001; IGNX001; IGX-0107 and IGX-0109 | Phase 1 Clinical | IgGenix Inc | Peanut Hypersensitivity | Details |
| Omalizumab (Tianchen Biomedical) | Phase 1 Clinical | Longbio Pharma (Suzhou) Co Ltd | Chronic Urticaria | Details | |
| Anti-IgE allergy vaccine (United Biomedical) | Phase 1 Clinical | United Biomedical Inc | Hypersensitivity | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Omalizumab biosimilar (IBC Generium) | GNR-044 | Approved | Ibc Generium | Genolair | Russian Federation | Asthma; Chronic Urticaria | Generium Pharmaceuticals | 2022-02-09 | Asthma; Chronic Urticaria | Details |
| Omalizumab biosimilar (Mabtech) | STI-004; CMAB007; CMAB-007 | Approved | Shanghai Zhangjiang Biotechnology Co Ltd | Aomaishu, 奥迈舒 | Mainland China | Asthma | Taizhou Mabtech Pharmaceutical Co Ltd | 2023-05-19 | Allergic asthma; Asthma; Chronic Urticaria | Details |
| Omalizumab biosimilar (Synermore Biologics) | SYN-008 | Approved | Synermore Biologics (Suzhou) Co Ltd | Kelingda, 可令达, 恩益坦 | Mainland China | Chronic Urticaria | Jushi Biopharmaceutical Co Ltd | 2024-09-26 | Allergic asthma; Chronic Urticaria | Details |
| Omalizumab biosimilar（Celltrion） | CT-P39 | Approved | Celltrion Inc | Omlyclo | EU | Allergic asthma; Sinusitis; Chronic rhinosinusitis with nasal polyps (CRSwNP) | Celltrion Healthcare Hungary Kft | 2024-05-16 | Allergic asthma; Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Food Hypersensitivity; Nasal Polyps; Sinusitis; Urticaria | Details |
| Omalizumab | GN-1560; RG-3648; IGE-025A; rhuMAb-E25; R-3648; E-25; IGE-025 | Approved | Genentech Inc, Novartis Pharma Ag | Xolair, 茁乐 | Australia | Asthma; Chronic Urticaria | null | 2002-01-01 | Allergic asthma; Anaphylaxis; Angioedema; Asthma; Autism Spectrum Disorder; Bronchitis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Colonic Neoplasms; Coronavirus Disease 2019 (COVID-19); Dermatitis, Atopic; Drug Hypersensitivity; Eosinophilic Esophagitis; Esophagitis; Food Hypersensitivity; Gastroenteritis; Hypersensitivity; Immune System Diseases; Infertility, Female; Job Syndrome; Lupus Erythematosus, Systemic; Mastocytosis; Milk Hypersensitivity; Nasal Polyps; Peanut Hypersensitivity; Pemphigoid, Bullous; Pulmonary Disease, Chronic Obstructive; Rhinitis; Rhinitis, Allergic, Seasonal; Sinusitis; Sjogren's Syndrome; Symptomatic Dermographism; Urticaria | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: